Apricus Biosciences (APRI) Trading Up 9.8%

Shares of Apricus Biosciences Inc (NASDAQ:APRI) were up 9.8% on Wednesday . The stock traded as high as $2.04 and last traded at $2.02. Approximately 918,900 shares were traded during trading, an increase of 61% from the average daily volume of 569,750 shares. The stock had previously closed at $1.84.

Several analysts have weighed in on APRI shares. HC Wainwright reaffirmed a “buy” rating and set a $4.50 price objective on shares of Apricus Biosciences in a research note on Friday, November 3rd. Zacks Investment Research upgraded shares of Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, October 31st.

The company has a market capitalization of $32.10, a PE ratio of 3.64 and a beta of 0.43.

Apricus Biosciences (NASDAQ:APRI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.15). During the same period in the prior year, the business posted ($0.19) EPS. equities research analysts forecast that Apricus Biosciences Inc will post -0.6 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Apricus Biosciences (APRI) Trading Up 9.8%” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3126578/apricus-biosciences-apri-trading-up-9-8.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.